Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI EBITDA Margin
EBITDA as a percentage of revenue.
Treace Medical Concepts, Inc.NASDAQ: TMCI
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -32.8%
EBITDA Margin was -32.8% in Q1 FY2026, down 9.7 pp from a year earlier. On a trailing-twelve-month basis it was -22.3%, down 4.0 pp year over year. Over 3 fiscal years it widened by 5.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -16.9% for the fiscal year ending Dec 2026, up from -20.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -32.8%-24.6 pp QoQ
- Last fiscal yearDec 2025
- -20.3%-0.2 pp YoY
- LTMMar 2026
- -22.3%-4.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.7 pp | -8.0 pp | +1.7 pp |
| 1 year | -0.2 pp | +3.4 pp | +3.6 pp |
| 3 years | +5.3 pp | +9.6 pp | +4.3 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -20.3%
- Year-over-year change
- -0.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -20.3% | -0.2pp |
| FY2024 | 2024-12-31 | -20.1% | +0.8pp |
| FY2023 | 2023-12-31 | -20.8% | +4.7pp |
| FY2022 | 2022-12-31 | -25.6% | -8.8pp |
| FY2021 | 2021-12-31 | -16.7% | — |
EBITDA Margin vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's LTM Mar 2026 EBITDA Margin of -22.3% is the 5th highest of the 8 companies compared; the peer median is -5.4%.
- Its year-over-year change of -4.0 pp is the 6th highest of 8, against a peer median of +3.5 pp.
- Over three fiscal years its change of +5.3 pp compares with a peer median of +41.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 17.9% | +11.6 pp | +41.2 pp | |
| LTM Mar 2026 | -2.7% | +3.5 pp | +2.1 pp | |
| LTM Mar 2026 | -4.6% | +6.2 pp | +28.7 pp | |
| LTM Mar 2026 | -5.4% | +6.2 pp | +18.3 pp | |
| LTM Mar 2026 | -22.3% | -4.0 pp | +5.3 pp | |
| LTM Mar 2026 | -33.9% | -19.3 pp | +89.0 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -60.2% | -2.1 pp | +78.9 pp |
| LTM Mar 2026 | -94.5% | -30.2 pp | +72.1 pp | |
| Peer median (excluding TMCI) | -5.4% | +3.5 pp | +41.2 pp | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 94.42M | 141.84M | 187.12M | 209.36M | 212.69M |
| Cost of Revenue | 16.89M | 27.52M | 35.18M | 41.09M | 42.94M |
| Gross Profit | 77.53M | 114.32M | 151.94M | 168.26M | 169.75M |
| Gross Margin | 82.1% | 80.6% | 81.2% | 80.4% | 79.8% |
| Research & Development | 10.2M | 13.58M | 15.44M | 20.59M | 20.28M |
| Selling, General & Admin | 83.84M | 137.57M | 187.93M | 203.36M | 203.62M |
| Operating Expenses | 94.04M | 149.16M | 203.37M | 223.95M | 223.91M |
| Depreciation & Amortization | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| EBITDA | (15.81M) | (36.28M) | (39.01M) | (42.07M) | (43.18M) |
| EBITDA Margin | -16.7% | -25.6% | -20.8% | -20.1% | -20.3% |
| Operating Income | (16.51M) | (34.84M) | (51.43M) | (55.69M) | (54.15M) |
| Operating Margin | -17.5% | -24.6% | -27.5% | -26.6% | -25.5% |
| Interest Income | 18K | 1.31M | 6.73M | 4.88M | 2.78M |
| Interest Expense | 4.06M | 4.4M | 5.17M | 5.26M | 5.32M |
| Other Income / Expenses | (4.04M) | (7.97M) | 1.9M | (55K) | (4.85M) |
| Income Before Tax | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Pre-Tax Margin | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Net Margin | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| EPS (Basic) | (0.38) | (0.77) | (0.81) | (0.90) | (0.93) |
| EPS (Diluted) | (0.38) | (0.77) | (0.81) | (0.90) | (0.93) |
| Weighted Avg Shares | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
| Weighted Avg Shares (Diluted) | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.